Research programme: anticancer antibodies - MMRGlobal

Drug Profile

Research programme: anticancer antibodies - MMRGlobal

Alternative Names: Anti-CD20 monoclonal antibodies - MMR Information Systems; Anti-CD20 monoclonal antibodies -MMRGlobal

Latest Information Update: 07 Feb 2015

Price : $50

At a glance

  • Originator Diversa
  • Developer MMRGlobal
  • Class Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Feb 2015 MMRGlobal has patent protection for methods of treatment using the anti-CD20 monoclonal antibodies in USA
  • 30 Nov 2011 Research programme: anticancer antibodies - MMR Information Systems is available for licensing as of 30 Nov 2011. http://www.mmrinformationsystems.com
  • 15 Jun 2010 MMR Information Systems is now called MMRGlobal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top